Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical...
September 17, 2025 09:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the...